Intralesional antimony for single lesions of Bolivian cutaneous Leishmaniasis

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages 1255-1260

  Soto, Jaime ^a   Rojas, Ernesto ^b   Guzman, Miguel ^b   Verduguez, Aleida ^b   Nena, Winne ^c   Maldonado, Maria ^c   Cruz, Mary ^b   Gracia, Lineth ^b   Villarroel, Darsi ^d   Alavi, Isidoro ^d   Toledo, Julia ^e   Berman, Jonathan ^f  

^a FUNDERMA Fundación Nacional de Dermatología   (United States)

^b UNIVERSIDAD MAYOR DE SAN SIMÓN   (Bolivia)

^c Hospital Local   (United States)

^d Hospital Regional Chapare   (Bolivia)

^e Centro de Investigaciones Bioclínicas   (Colombia)

^f AB Foundation   (United States)

Author keywords

Bolivia; cutaneous leishmaniasis; intralesional antimony; L. braziliensis; placebo

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; IMIDAZOLE DERIVATIVE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PLACEBO;

ADULT; ARTICLE; BOLIVIA; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOTHERAPY; DRUG EFFICACY; DRUG TOLERANCE; EPITHELIZATION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; LEISHMANIA BRAZILIENSIS; LOCAL THERAPY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN EDEMA; SKIN IRRITATION; SKIN LEISHMANIASIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMONY; ANTIPROTOZOAL AGENTS; BOLIVIA; CHILD; CRYOTHERAPY; DRUG TOXICITY; FEMALE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876009759     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit049     Document Type: Article

References (16)

1. Murray H, Berman J, Davies C, Saravia N. Advances in leishmaniasis. Lancet 2005; 366:1561-77. (Pubitemid 41540115)
2. Grimaldi G, Tesh R, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989; 41:687-725. (Pubitemid 20022744)
3. García A, Parrado R, Rojas E, Delgado R, Dujardin J-C, Reithinger R. Leishmaniases in Bolivia: comprehensive review and current status. Am J Trop Med Hyg 2009; 80:704-11.
4. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89:147-55. (Pubitemid 20254438)
5. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 1997; 126:232-6. (Pubitemid 27061579)
6. Soto J, Arana B, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis: placebo-controlled multicenter study. Clin Infect Dis 2004; 38:1266-72. (Pubitemid 38608569)
7. Herwaldt B, Arana B, Navin T. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518-27.
8. Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of New World cutaneous leishmaniasis. Am J Trop Med Hyg 2004; 71:577-81. (Pubitemid 39601154)
9. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78: 210-11. (Pubitemid 351844550)
10. Herwaldt B, Berman J. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
11. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatology 2004; 43:281-3. (Pubitemid 38559545)
12. Oliveira-Neto MP, Schubach A, Mattos M, Gonfalves da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (v.) braziliensis transmission. Int J Dermatol 1997; 36:463-8. (Pubitemid 27319639)
13. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26:56-8. (Pubitemid 28068155)
14. Layegh P, Pezeshkpoor F, Soruri A, Naviafar P, Moghiman T. Efficacy of cryotherapy versus intralesional meglumine antimoniate (Glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg 2009; 80:172-5.
15. Garcia L, Kindt A, Bermudez H, et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCRbased assay targeting heat shock protein 70 genes. J Clin Microbiol 2004; 42:2294-7. (Pubitemid 38637869)
16. Blum J, Lockwood D, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 2012; 4:153-63.